NCT02500797 · OUTCOME

PFS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery · Source last updated 2023-10-17

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Time from randomization to first of either disease progression or death from any cause, assessed up to 3 years

What was measured

Evaluated using Kaplan-Meier methodology.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Evaluated using Kaplan-Meier methodology.
reporting Status: NOT_POSTED
time Frame: Time from randomization to first of either disease progression or death from any cause, assessed up to 3 years
title: PFS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice